On September 16, Gilead Sciences, Inc. (NASDAQ:GILD) expanded the scope of its six royalty-free voluntary licensing agreements for lenacapavir to cover an investigational once-yearly formulation for HIV pre-exposure prophylaxis (PrEP). Covering 120 high-incidence, lower-income countries, the expanded framework aims to accelerate manufacturing readiness and technology transfer during the ongoing Phase 3 PURPOSE 365 study.
Following unprecedented efficacy demonstrated by twice-yearly lenacapavir in PURPOSE 1 and PURPOSE 2, an approved once-yearly option would mark a major shift in long-acting prevention. By expanding access mechanisms while clinical development is underway, Gilead is extending its global access strategy to secure early market dominance across developing and developed markets alike.
You May Also Want To Read: Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
You May Also Want To Read: Gilead vs. Medtronic: Which Healthcare Stock Offers the Better Mix of Growth and Income?
Bull Case: Commercial Dominance and Pipeline Expansion
For Gilead Sciences, Inc., early access planning for once-yearly lenacapavir reinforces the moat around its core HIV franchise. In Q2 2026, HIV product sales increased 12% year-over-year to $5.7 billion, propelled by Biktarvy ($3.8 billion, up 7%) and Descovy ($967 million, up 48%). Base product sales excluding Veklury grew 10% to $7.6 billion, generating $3.6 billion in quarterly operating cash flow.
Beyond HIV, Gilead generated 26% growth in Trodelvy ($457 million) and added Livdelzi to its liver disease business, demonstrating pipeline diversification. Establishing royalty-free global distribution for lenacapavir builds commercial infrastructure that expands patient reach without sacrificing high-margin commercial markets, positioning Gilead to convert pipeline milestones into long-term cash generation.
Bear Case: Earnings Distortions and Headwinds Outside HIV
Despite top-line strength, Gilead reported a Q2 2026 GAAP diluted loss per share of $(8.45) and a non-GAAP loss per share of $(6.75). The losses reflect $(9.08) per share in acquired in-process R&D (IPR&D) charges totaling $11.2 billion—primarily driven by the acquisitions of Arcellx ($7.0 billion), Tubulis ($3.1 billion), and Ouro Medicines ($1.0 billion). Cash, cash equivalents, and marketable securities dropped from $10.6 billion at year-end 2025 to $3.2 billion as cash outflows for acquisitions reached $11.3 billion year-to-date.
Furthermore, oncology and legacy lines faced pressure: Cell Therapy sales fell 14% to $417 million due to competitive headwinds, while Veklury sales plummeted 81% to $23 million as COVID-19 hospitalizations declined. The upfront costs of global access initiatives and heavy R&D spending heighten Gilead’s reliance on its HIV portfolio to cushion underperforming units.
Don’t Miss: Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Market Sentiment & Conclusion
Market sentiment remains cautiously optimistic. Investors favor the sustained revenue growth in HIV and Oncology, but heavy IPR&D write-offs and declining cash reserves keep near-term valuation multiples bound to pipeline execution.
Gilead Sciences, Inc.’s lenacapavir licensing expansion converts clinical progress into early structural adoption. While heavy acquisition charges and product declines create earnings volatility, the growth of core HIV medicines and strong operating cash flow provide the foundation needed to realize the full upside of its next-generation PrEP pipeline.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
